

## Product datasheet for **TL306548V**

### ASB2 Human shRNA Lentiviral Particle (Locus ID 51676)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	ASB2 Human shRNA Lentiviral Particle (Locus ID 51676)
Locus ID:	51676
Synonyms:	ASB-2
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ASB2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, $>10^7$ TU/ml.
RefSeq:	<a href="#">NM_001202429</a> , <a href="#">NM_016150</a> , <a href="#">NM_016150.1</a> , <a href="#">NM_016150.2</a> , <a href="#">NM_016150.3</a> , <a href="#">NM_016150.4</a> , <a href="#">NM_001202429.1</a> , <a href="#">BC032354</a> , <a href="#">BC032354.1</a> , <a href="#">NM_001202429.2</a>
UniProt ID:	<a href="#">Q96Q27</a>
Summary:	This gene encodes a member of the ankyrin repeat and SOCS box-containing (ASB) protein family. These proteins play a role in protein degradation by coupling suppressor of cytokine signalling (SOCS) proteins with the elongin BC complex. The encoded protein is a subunit of a multimeric E3 ubiquitin ligase complex that mediates the degradation of actin-binding proteins. This gene plays a role in retinoic acid-induced growth inhibition and differentiation of myeloid leukemia cells. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jan 2011]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).